Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab + PCD for newly diagnosed multiple myeloma with severe renal dysfunction
ChiCTR2400093422Phase 4Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Dec 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of daratumumab, bortezomib, cyclophosphamide and dexamethasone in multiple myeloma (MM), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Renal response rate after 4 courses of treatment. Started Dec 2024; status: recruiting.
02
Drugs
daratumumabbortezomibcyclophosphamidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400093422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093422.